CClinicalTrials.gg
Active, not recruitingNCT06277518Updated Feb 26, 2024

System for Postoperative Admission to ICU for Patients With Digestive System Malignancy

An observational study in Intensive Care Unit Syndrome, sponsored by General Hospital of Ningxia Medical University. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by General Hospital of Ningxia Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
2,000
Sex
All
01

Study summary

Postoperative admission to ICU for patients with digestive system tumors is one of the most common postoperative complications of all non-cardiac surgeries. The study found that supportive treatment of critically ill patients admitted to ICU after surgery was conducive to reducing mortality, and the most common complications of postoperative ICU admission were infections, especially respiratory infections and surgical site infections. A growing body of evidence supports that ICU stays are expensive, always occupy major hospital resources, and are associated with the worst outcomes. To date, there is insufficient evidence to determine which patients with digestive system tumors benefit the most from being admitted to the ICU after surgery. Therefore, this study intends to adopt retrospective study to determine the risk factors of postoperative ICU transfer for patients with digestive system malignant tumor, and build a risk prediction model for postoperative ICU admission, so as to guide the decision of postoperative ICU transfer for patients with digestive system malignant tumor.

Read the detailed description

The incidence of malignant tumors of digestive system is increasing year by year in the world, and surgical treatment is the first choice for malignant tumors of digestive system. Most of these patients were elderly, had more complications before surgery, had greater surgical trauma, and had a high proportion of postoperative ICU admission. In recent three years, 28.1% of patients with malignant tumor of digestive system were admitted to ICU after surgery. The study found that postoperative ICU care in critically ill patients was conducive to reducing mortality, while non-essential postoperative ICU care in some patients was associated with the worst outcome. At present, there is still a lack of accurate and reliable decision making system for postoperative admission to ICU for patients with digestive system malignancies at home and abroad. Therefore, this project intends to establish a predictive model for postoperative ICU admission of patients with malignant tumors of the digestive system, develop a friendly interface that is convenient for medical care, help medical care quickly determine the biggest beneficiaries of postoperative ICU admission, rationally allocate medical resources, improve medical quality, reduce medical costs, ensure perioperative safety of patients, and promote postoperative rehabilitation of patients. At present, there is still a lack of accurate and reliable decision making system for postoperative admission to ICU for patients with digestive system malignancies at home and abroad. Therefore, this project intends to establish a predictive model for postoperative ICU admission of patients with malignant tumors of the digestive system, develop a friendly interface that is convenient for medical care, help medical care quickly determine the biggest beneficiaries of postoperative ICU admission, rationally allocate medical resources, improve medical quality, reduce medical costs, ensure perioperative safety of patients, and promote postoperative rehabilitation of patients.

02

Conditions studied

  • Intensive Care Unit Syndrome

Browse trials for

Keywords

  • Malignant tumors of digestive system
  • Intensive care Unit
  • risk factors
  • predictive models
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 2,000 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 102 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgery for malignant tumors of digestive system under general anesthesia in Shaanxi Provincial Cancer Hospital and Ningxia Medical University General Hospital from January 2019 to December 2023

Inclusion criteria

  • Postoperative patients with malignant tumor of digestive system under general anesthesia, ASA Ⅱ\~ Ⅳ

Exclusion criteria

Exclusion Criteria:

  • Emergency operation, operation stopped after entering the operating room, ASA > Ⅳ
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
2,000 participants (actual)
Patient registry
No

Groups and cohorts

  • observation group,

    the risk factors of patients with malignant tumors of digestive system meeting the inclusion criteria were observed without special intervention

    Procedure: Surgery for malignant tumors of the digestive system

Interventions

  • ProcedureSurgery for malignant tumors of the digestive system

    Related treatment or palliative surgery under general anesthesia for digestive system malignancies

06

What researchers measure

Primary outcomes

  1. admitted to ICU after surgery

    whether the patient was admitted to ICU after surgery or within three days

    Time frame: the day and three days after surgery

07

Study locations

1 site
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277518
Lead sponsor
General Hospital of Ningxia Medical University
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Sep 20, 2023
Primary completion
Dec 2025 (estimated)
Completion
Jun 20, 2026 (estimated)
Last update
Feb 26, 2024

Study contacts

Liqin Deng, M.D
principal investigator · General Hospital of Ningxia Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion